-
公开(公告)号：US20210236471A1
公开(公告)日：2021-08-05
申请号：US17164654
申请日：2021-02-01
发明人： Jay Edward Wrobel , Allen B. Reitz , Jeffrey Claude Pelletier , Garry Robert Smith , Haiyan Bian
IPC分类号： A61K31/428 , A61P25/00 , A61P25/28 , A61K38/06 , C07K5/083 , C07K5/087 , C07D277/82 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K38/05 , A61K45/06 , C07D417/12 , C07K5/062 , A61K9/00 , A61K9/16 , A61K9/20
摘要： Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
-
公开(公告)号：US20210236470A1
公开(公告)日：2021-08-05
申请号：US17151582
申请日：2021-01-18
发明人： Jay Edward Wrobel , Allen B. Reitz , Jeffrey Claude Pelletier , Garry Robert Smith , Haiyan Bian
IPC分类号： A61K31/428 , A61P25/00 , A61P25/28 , A61K38/06 , C07K5/083 , C07K5/087 , C07D277/82 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K38/05 , A61K45/06 , C07D417/12 , C07K5/062 , A61K9/00 , A61K9/16 , A61K9/20
摘要： Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
-
公开(公告)号：US12005046B2
公开(公告)日：2024-06-11
申请号：US17164654
申请日：2021-02-01
发明人： Jay Edward Wrobel , Allen B. Reitz , Jeffrey Claude Pelletier , Garry Robert Smith , Haiyan Bian
IPC分类号： A61K31/428 , A61K9/00 , A61K9/16 , A61K9/20 , A61K31/454 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K38/05 , A61K38/06 , A61K39/00 , A61K45/06 , A61P25/00 , A61P25/28 , A61P35/00 , C07D277/82 , C07D417/12 , C07K5/062 , C07K5/083 , C07K5/087
CPC分类号： A61K31/428 , A61K9/006 , A61K9/1617 , A61K9/2004 , A61K31/454 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K38/05 , A61K38/06 , A61K39/4636 , A61K45/06 , A61P25/00 , A61P25/28 , A61P35/00 , C07D277/82 , C07D417/12 , C07K5/06026 , C07K5/0806 , C07K5/0808 , C07K5/0812 , A61K2300/00
摘要： Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
-
公开(公告)号：US11911369B2
公开(公告)日：2024-02-27
申请号：US16865498
申请日：2020-05-04
发明人： Jay Edward Wrobel , Allen B. Reitz , Jeffery Claude Pelletier , Garry Robert Smith , Haiyan Bian
IPC分类号： C07D277/82 , A61K31/428 , A61P25/00 , A61P25/28 , A61K38/06 , C07K5/083 , C07K5/087 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K38/05 , A61K45/06 , C07D417/12 , C07K5/062 , A61K9/00 , A61K9/16 , A61K9/20 , A61K9/48
CPC分类号： A61K31/428 , A61K9/006 , A61K9/1617 , A61K9/2004 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K38/05 , A61K38/06 , A61K45/06 , A61P25/00 , A61P25/28 , C07D277/82 , C07D417/12 , C07K5/06026 , C07K5/0806 , C07K5/0808 , C07K5/0812 , A61K9/0056 , A61K9/2018 , A61K9/2063 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K2300/00
摘要： Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
-
公开(公告)号：US20230017637A1
公开(公告)日：2023-01-19
申请号：US17367484
申请日：2021-07-05
发明人： Jay Edward Wrobel , Allen B. Reitz , Jeffery Claude Pelletier , Garry Robert Smith , Haiyan Bian
IPC分类号： A61K31/428 , A61P25/00 , A61P25/28 , A61K38/06 , C07K5/083 , C07K5/087 , C07D277/82 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K38/05 , A61K45/06 , C07D417/12 , C07K5/062 , A61K9/00 , A61K9/16 , A61K9/20
摘要： Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
-
公开(公告)号：US20220396555A1
公开(公告)日：2022-12-15
申请号：US16865498
申请日：2020-05-04
发明人： Jay Edward Wrobel , Allen B. Reitz , Jeffery Claude Pelletier , Garry Robert Smith , Haiyan Bian
IPC分类号： C07D277/82
摘要： Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
-
公开(公告)号：US10905681B2
公开(公告)日：2021-02-02
申请号：US16449948
申请日：2019-06-24
发明人： Jay Edward Wrobel , Allen B. Reitz , Jefferey Claude Pelletier , Garry Robert Smith , Haiyan Bian
IPC分类号： A61K31/428 , A61P25/28 , C07D277/82 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K38/05 , A61K45/06 , C07D417/12 , C07K5/062 , A61K9/00 , A61K9/16 , A61K9/20 , A61P25/00 , C07K5/083 , C07K5/087 , A61K38/06
摘要： Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
-
公开(公告)号：US20200289475A1
公开(公告)日：2020-09-17
申请号：US16449948
申请日：2019-06-24
发明人： Jay Edward Wrobel , Allen B. Reitz , Jefferey Claude Pelletier , Garry Robert Smith , Haiyan Bian
IPC分类号： A61K31/428 , A61P25/00 , A61P25/28 , C07D277/82 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K38/05 , A61K45/06 , C07D417/12 , C07K5/062 , A61K9/00 , A61K9/16 , A61K9/20
摘要： Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
-
公开(公告)号：US20200085794A1
公开(公告)日：2020-03-19
申请号：US16689150
申请日：2019-11-20
发明人： Jay Edward Wrobel , Allen B. Reitz , Jeffery Claude Pelletier , Garry Robert Smith , Haiyan Bian
IPC分类号： A61K31/428 , A61P25/00 , A61P25/28 , C07D277/82 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K38/05 , A61K45/06 , C07D417/12 , C07K5/062 , A61K9/00 , A61K9/16 , A61K9/20
摘要： Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
-
公开(公告)号：US12005047B2
公开(公告)日：2024-06-11
申请号：US18361837
申请日：2023-07-29
发明人： Jay Edward Wrobel , Allen B. Reitz , Jeffery Claude Pelletier , Garry Robert Smith , Haiyan Bian
IPC分类号： A61K31/428 , A61K9/00 , A61K9/16 , A61K9/20 , A61K31/454 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K38/05 , A61K38/06 , A61K39/00 , A61K45/06 , A61P25/00 , A61P25/28 , A61P35/00 , C07D277/82 , C07D417/12 , C07K5/062 , C07K5/083 , C07K5/087
CPC分类号： A61K31/428 , A61K9/006 , A61K9/1617 , A61K9/2004 , A61K31/454 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K38/05 , A61K38/06 , A61K39/4636 , A61K45/06 , A61P25/00 , A61P25/28 , A61P35/00 , C07D277/82 , C07D417/12 , C07K5/06026 , C07K5/0806 , C07K5/0808 , C07K5/0812 , A61K2300/00
摘要： Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.019 秒)
